Ophthalmology Times Europe

The new extended treatment intervals for nAMD and DME open exciting possibilities for patients. We’ve planned a lively CME conversation with experts Arshad M. Khanani, MD, MA, FASRS; Carl J. Danzig, MD, FASRS; and Jennifer I. Lim, MD, FARVO. Learn more: https://bit.ly/45Lje33 #aao2024

In case you missed it: Our June cover story focuses on metabolomics and the role of metabolites as a means of understanding glaucoma. How can this area of study inform how practitioners approach patients' unique needs? “The current diagnostic challenges are the asymptomatic nature of glaucoma and the limitations of the traditional diagnostic methods," says Neeru Vallabh. "While genetic studies have been hugely successful in improving our understanding of the disease, the mechanisms through which genetic factors interact with non-genetic factors and lead to glaucoma are not well understood." Learn about the capabilities, limitations and future of metabolomics here: https://lnkd.in/d8Phhyfd

🚨 June Issue Alert! 🚨 The latest edition of Ophthalmology Times Europe is out now. Stay ahead with the latest research and insights in the field of ophthalmology. Access the June 2024 issue here: https://bit.ly/4chu976

In a welcome letter, Armin Scharrer, MD, President of the DOC, addressed his colleagues and provided a brief preview of the comprehensive, practice-oriented programme. https://lnkd.in/ebSxb487

With the ability to gather large data sets more accurately and easily for analysis, researchers can discover trends in the general health of the population and how subpopulations are—or are not—having their needs met. These analyses can empower better treatment and even motivate additional treatment options or strategies to fill the gaps in treatment needs. From our colleagues at Optometry Times and Modern Retina, how real-world insights can clear the path to trends and strategies to meet patients’ needs. https://lnkd.in/e27TZ6yG

Espansione Group's flagship, light-based technology has received approval for applications in the anterior and posterior segments, including AMD, blepharitis, chalazion, ocular rosacea, post-blepharoplasty complications and more. https://lnkd.in/e9sj2D2Y

Plasma emission can act as a therapeutic for blepharitis, dry eye and other ocular disease. Read about this non-ablative treatment in our June issue, out now: https://lnkd.in/eq2Zy84k

Discover expert insights on IOL selection techniques straight from renowned opinion leaders. Maximize patient outcomes by optimizing IOL selection using state-of-the-art diagnostic tools and overcoming postimplantation challenges. Watch Now! https://ow.ly/IfXl50QUiO1

The US FDA issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen. Both biosimilars are suitable for treating patients with nAMD, macular oedema following retinal vein occlusion, diabetic macular oedema and/or diabetic retinopathy. Read more: https://lnkd.in/eF5RAxsf

🚨 May Issue Alert! 🚨 The latest edition of Ophthalmology Times Europe is out now. Stay ahead with the latest research and insights in the field of ophthalmology. Access the May 2024 issue here: https://bit.ly/4dMLSUO